Evidence map›Paper›PMID 40401155›Full record

ArticleBrain communications2025

Two distinct trajectories of brain volume loss in myotonic dystrophy type 1 via machine learning.

Tomoki Imokawa, Hiroyuki Maki, Daichi Sone, Risa Kagaya, Yoko Shigemoto, Yukio Kimura, Hiroshi Matsuda, Yuji Takahashi, Ukihide Tateishi, Noriko Sato

Abstract read
In one paragraph

Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tomoki ImokawaDepartment of Radiology, National Centre Hospital, National Centre of Neurology and Psychiatry, 187-8551 Kodaira, Tokyo, Japan.
Hiroyuki MakiDepartment of Radiology, National Centre Hospital, National Centre of Neurology and Psychiatry, 187-8551 Kodaira, Tokyo, Japan.
Daichi SoneDepartment of Psychiatry, Jikei University School of Medicine, 105-0003 Minato-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9617-706X
Risa KagayaDepartment of Radiology, National Centre Hospital, National Centre of Neurology and Psychiatry, 187-8551 Kodaira, Tokyo, Japan.
Yoko ShigemotoDepartment of Radiology, National Centre Hospital, National Centre of Neurology and Psychiatry, 187-8551 Kodaira, Tokyo, Japan.
Yukio KimuraDepartment of Radiology, National Centre Hospital, National Centre of Neurology and Psychiatry, 187-8551 Kodaira, Tokyo, Japan.
Hiroshi MatsudaDepartment of Biofunctional Imaging, Fukushima Medical University, 960-1295 Fukushima-shi, Fukushima, Japan.
Yuji TakahashiDepartment of Neurology, National Centre Hospital, National Centre of Neurology and Psychiatry, 187-8551 Kodaira, Tokyo, Japan.
Ukihide TateishiDepartment of Diagnostic Radiology, Institute of Science Tokyo, 113-8510 Bunkyo-ku, Tokyo, Japan.ORCID https://orcid.org/0000-0002-6548-8698
Noriko SatoDepartment of Radiology, National Centre Hospital, National Centre of Neurology and Psychiatry, 187-8551 Kodaira, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myotonic dystrophy Type 1 is a disorder that affects multiple systems, including the muscles and the CNS. Previous studies have primarily used voxel-based morphometry to examine areas of brain volume reduction and their correlation with symptoms; however, consistent findings have not been obtained. Subtype and stage inference is an unsupervised machine learning algorithm that elucidates disease progression and subtypes from cross-sectional data. In this study, we used Subtype and Stage Inference to analyse the morphometric MRI data of patients with myotonic dystrophy Type 1 to reveal the detailed trajectories of brain volume loss and to explore the potential of morphometric MRI as a biomarker for myotonic dystrophy Type 1. We examined 60 patients with myotonic dystrophy Type 1 and 50 age- and sex-matched controls. The patients with myotonic dystrophy Type 1 had a median age of 44 years (range 20-67 years) and included 32 males. Using three-dimensional T1-weighted MRI images, we analysed the subtypes of brain involvement and their respective trajectories of brain volume loss with subtype and stage inference. Additionally, we examined the differences and correlations in clinical and brain morphological indicators between the identified subtypes and controls. Subtype and stage inference revealed two subtypes: cortical and subcortical. In the cortical subtype, volume reduction began in the precentral gyrus and spread primarily to the cerebral cortex. In the subcortical subtype, it progressed early in the putamen, thalamus, hippocampus and amygdala. Examination of clinical indicators showed that despite the younger age of the subcortical subtype compared to the cortical subtype, mini-mental state examination scores were significantly lower in the subcortical subtype and negatively correlated with subcortical probability. The total intracranial volume, a marker of maximal brain growth, was significantly smaller in the cortical subtype; however, it was not smaller in the subcortical subtype than in controls. Furthermore, the subcortical subtype showed a larger total ventricle volume than both the controls and the cortical subtype. In contrast, its total brain parenchymal volume was lower than that of the controls, similar to the cortical subtype. These results suggest early childhood brain development differences between the two subtypes. Using Subtype and Stage Inference, we identified two subtypes of myotonic dystrophy Type 1 and demonstrated the potential of morphological MRI as a biomarker for cognitive impairment and brain developmental disorders. Machine learning can aid in stratifying myotonic dystrophy Type 1 in clinical settings and contribute to the elucidation of its complex pathophysiology.

Indexed as

dementiamuscular dystrophyneurodegenerative diseaseSuStaIntauopathy

Identifiers

PMID40401155
PMCPMC12094019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.